← All trials
NCT05751967
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2023
- Primary completion
- Dec 1, 2024
- Completion date
- Dec 1, 2025
- First posted
- Mar 2, 2023
- Last posted
- Mar 6, 2023
- Enrollment
- 150
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- People's Liberation Army of ChinaLead sponsor
- People's Liberation Army of ChinaReponsible party - principal investigator
- People's Liberation Army of ChinaSponsor investigator
- People's Liberation Army of ChinaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.